Ankur Lodha, MD
Interventional Cardiology · Lafayette, LANPI 1598951436
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 52 manufacturers reported payments, led by Shockwave Medical, Inc at 24.7% of the total. Among interventional cardiology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,301 payments — averaging $492.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shockwave Medical, Inc$158K
- Terumo Medical Corporation$141K
- Cardiovascular Systems Inc.$83K
- Boston Scientific$73K
- Surmodics, Inc.$50K
- Silk Road Medical, Inc.$44K
- plus $90K from 46 others
Across 42 payments — averaging $7245.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Terumo Medical Corporation$151K
- Philips North America LLC$101K
- Cardiovascular Systems Inc.$44K
- Abbott$6K
- Surmodics, Inc.$2K
What the payments were for
- Consulting fees$318,33850%
- Speaking & faculty fees$212,06033%
- Travel & lodging$75,36012%
- Food & beverage$34,6795%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$154,770
- Navicross$71,172
- ENROUTE Transcarotid Neuroprotection System$68,784
- GlideWire$57,769
- Peripheral Orbital Atherectomy System$49,471
- Sublime 014 Rx PTA Balloon Dilatation Catheter$46,793
- ENROUTE Transcarotid Stent$42,020
- R2P MISAGO$40,515
- TR Band$37,904
- METACROSS OTW$37,800
- Diamondback Peripheral$36,886
- GENERAL - THERAPIES$33,768
- Glidesheath$33,721
- Sublime Radial Access 018 RX PTA Dilatation Catheter$32,692
- Pounce Thrombectomy System$30,560
- ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter$26,662
- Sublime Radial Access Guide Sheath$26,591
- Pounce Venous Thrombectomy System$21,077
- GLIDESHEATH SLENDER$16,775
- GORE VIABAHN VBX Balloon Expandable Endo$15,485
How this compares
$640,437 in reported general payments places this provider in the 95th percentile of 171 interventional cardiology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 645 | $574,032 |
| EntrestoSacubitril/Valsartan | 267 | $259,806 |
| XareltoRivaroxaban | 262 | $237,636 |
| Repatha SureclickEvolocumab | 137 | $95,275 |
| FarxigaDapagliflozin Propanediol | 39 | $25,445 |
| JardianceEmpagliflozin | 33 | $19,985 |
| Ranolazine ErRanolazine | 202 | $14,374 |
| ClopidogrelClopidogrel Bisulfate | 1,090 | $8,815 |
| Atorvastatin Calcium | 1,036 | $8,538 |
| Metoprolol Succinate | 755 | $7,481 |
| Rosuvastatin Calcium | 610 | $7,050 |
| Praluent PenAlirocumab | 14 | $6,889 |
| Ezetimibe | 308 | $5,792 |
| Carvedilol | 705 | $5,235 |
| Olmesartan Medoxomil | 198 | $4,009 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $500 | $574,032645 claims |
| NovartisEntresto | $457 | $259,806267 claims |
| Johnson & JohnsonXarelto | $490 | $237,636262 claims |
| AstraZenecaFarxiga | $58 | $25,44539 claims |
| Boehringer IngelheimJardiance | $274 | $19,98533 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 171 interventional cardiology providers in Louisiana.
Other interventional cardiology in Lafayette
- Agostino IngraldiLafayette$315K
- Louis SalvaggioLafayette$214K
- Eric ThomasseeLafayette$149K
- Amit AminLafayette$82K
- Raghotham PatlolaLafayette$76K
- Craig WalkerHouma$5M
- Denzil MoraesBaton Rouge$901K
- Rajan PatelNew Orleans$517K
- Steven BaileyShreveport$305K
- James JenkinsNew Orleans$235K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.